Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study

European Journal of Cancer

Volumn 44, Issue 17, 2008, Pages 2608-2614

  Bodnar, Lubomir ^a   Wcislo, Gabriel ^a   Gasowska Bodnar, Agnieszka ^b   Synowiec, Agnieszka ^a   Szarlej Wcisło, Katarzyna ^a   Szczylik, Cezary ^a  

^a The Health Services   (Poland)

^b Military Institute   (Poland)

Author keywords

Cisplatin; Magnesium; Ovarian cancer; Renal function; Side effect

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CREATININE; MAGNESIUM; MAGNESIUM CARBONATE; MAGNESIUM SALT; MAGNESIUM SULFATE; PACLITAXEL; PLACEBO;

ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; EPITHELIUM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY TUBULE DAMAGE; LEUKOPENIA; MAGNESIUM BLOOD LEVEL; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY DISEASES; MAGNESIUM; MAGNESIUM SULFATE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RENAL AGENTS;

EID: 55249106406     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.08.005     Document Type: Article

References (29)

1. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Eng J Med 334 (1996) 1-6
2. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel and cisplatin in patients with cisplatin and paclitaxel in patients with opptimally reseected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
3. Daugaard G., Abildgaard U., Holstein-Rathlou N.H., et al. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44 (1988) 164-172
4. Lebwohl D. Canetta R: Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer 34 (1998) 1522-1534
5. Jongh F.E., Veen R.N., Veltman S.J., et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88 (2003) 1199-1206
6. Dobyan D.C., Levi J., Jacobs C., et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213 (1980) 551-556
7. Tsuruya K., Ninomiya T., Tokumoto M., et al. Direct involvement of the receptormediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63 (2003) 72-82
8. Park M.S., De Leon M., and Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 13 (2002) 858-865
9. Brady H.R., Kone B.C., Stromski M.E., et al. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am J Physiol 258 (1990) F1181-F1187
10. Schilsky R.L., and Anderson T. Hypomagneasemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90 (1979) 929-931
11. Sobrero A., Guglielmi A., Aschele C., et al. Current strategies to reduce cisplatin toxicity. J Chemother 2 (1990) 3-7
12. Costa M., Castro I., Neto A.L., et al. Cyclosporin A tubular effects contribute to nephrotoxicity: role for Ca2+ and Mg2+ ions. Nephrol Dial Transplant 18 (2003) 2262-2268
13. Holzmacher R., Kendziorski C., Hofman R., et al. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 20 (2005) 1456-1462
14. Lajer H., Kristensen M., Hansen H.H., et al. Magnesium depletion enhances cisplatininduced nephrotoxicity. Cancer Chemother Pharmacol 56 (2005) 535-542
15. Ashraf M., Riggs J.E., Wearden S., and Scotchel P. Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynecol Oncol 37 (1990) 29-33
16. Martin M., Diaz-Rubio E., Casado A., López Vega J.M., Sastre J., and Almenarez J. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 15 (1992) 348-351
17. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
18. Common Terminology Criteria for Adverse Events, Version 3.0, revised June 10, 2003. National Cancer Institute, http://ctep.cancer.gov/forms/CTCAEv3.pdf.
19. Townsend D.M., Deng M., Zhang L., et al. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14 (2003) 1-10
20. Ciarimboli G., Ludwig T., Lang D., et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167 (2005) 1477-1484
21. Willox J.C., McAllister E.J., Sangster G., et al. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54 (1986) 19-23
22. Yao X., Panichpisal K., Kurtzman N., et al. Cisplatin nephrotoxicity: a review. Am J Med Sci 334 (2007) 115-124
23. Yuan J., Zhou J., Chen B.C., and Zhang. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc 37 (2005) 1892-1895
24. Leeuwenkamp O.R., Neijt J.P., van der Vijgh W.J., and Pinedo H.M. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate. Eur J Cancer 27 (1991) 1243-1247
25. Bokemeyer C., Fels L.M., Dunn T., et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer 74 (1996) 2036-2041
26. Benoehr P., Krueth P., Bokemeyer C., Grenz A., Osswald H., and Hartmann J.T. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol 16 (2005) 452-458
27. Santini V., and Giles F.J. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 84 (1999) 1035-1042
28. Hartmann J.T., von Vangerow A., Fels L.M., et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 84 (2001) 313-320
29. Hartmann J.T., Fels L.M., Knop S., Stolt H., Kanz L., and Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumours. Invest New Drugs 18 (2000) 281-289